Neoadjuvant apatinib-based regimens achieve 93% R0 resection rate in resectable gastric and esophageal junction cancers
Apatinib shows promise for patients with gastric and esophageal cancer
This single-arm meta-analysis of 975 patients evaluated neoadjuvant apatinib-based regimens for resectable gastric and gastroesophageal junc…
A new look at treatment data shows apatinib may help shrink tumors before surgery for patients with gastric and esophageal junction cancers.
PD-1/PD-L1 inhibitors with anti-angiogenic drugs achieve 48% ORR in recurrent or metastatic nasopharyngeal carcinoma
New drug combinations show promise for advanced nasopharyngeal cancer
This meta-analysis of 10 independent cohorts from 9 studies evaluates PD-1/PD-L1 inhibitors combined with small-molecule anti-angiogenic dru…
Combining certain immunotherapy drugs with anti-angiogenic agents shows a 48% response rate for patients with advanced nasopharyngeal cancer…
Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC
Treatment Naive Patients Show Better Survival with Camrelizumab and Apatinib
This meta-analysis evaluates the efficacy of camrelizumab plus apatinib for advanced or metastatic esophageal squamous cell carcinoma. The a…
Patients with advanced esophageal cancer who have not had prior treatment may see better survival rates when using a combination of camreliz…
Case report describes multimodal treatment and single-cell sequencing in NF1 patient with Malignant Triton Tumor
What happens when a rare cancer returns? One young woman's story offers a clue
A case report describes a 23-year-old woman with neurofibromatosis type 1 and Malignant Triton Tumor.
A 23-year-old woman with a rare chest tumor found disease stabilization after surgery failed, using a mix of chemotherapy, targeted therapy,…